Fibrinous Pericarditis – A Comprehensive Patient Guide

Overview

Fibrinous pericarditis is an inflammation of the pericardium (the thin, double‑layered sac that surrounds the heart) characterized by the deposition of fibrin—a protein involved in blood clotting—on the pericardial surfaces. The fibrin creates a rough, “bread‑and‑butter” appearance that can cause the layers of the pericardium to rub against each other, producing sharp chest pain.

• Who it affects: Adults of any age, but it is most common in people aged 30–60 years.
• Gender: Slight male predominance (≈ 55 % of cases).
• Prevalence: Acute pericarditis affects about 0.1 % of the general population each year; fibrinous type accounts for roughly 30‑40 % of those cases (Mayo Clinic, 2023).
• Geography: Incidence is similar worldwide, though higher rates are reported in regions with endemic infections such as tuberculosis.

Symptoms

The presentation can be variable, but the hallmark symptom is a sharp, pleuritic chest pain that worsens with inspiration or when lying flat and improves when sitting up or leaning forward.

Typical symptoms

• Chest pain: Sudden, stabbing, or tearing; often described as “sharp” or “knife‑like.”
• Friction rub: A high‑pitched, scratchy sound heard with a stethoscope, produced by the fibrinous layers rubbing together.
• Fever: Low‑grade (often < 38 °C/100.4 °F) in infectious or autoimmune causes.
• Shortness of breath: Usually mild, worsens when supine.
• Palpitations or irregular heartbeats: May be present if inflammation affects the underlying myocardium.
• Fatigue and malaise: General feeling of being unwell.

Atypical or associated symptoms

• Dry cough
• Swelling of the ankles (if tamponade or heart failure develops)
• Weight loss (particularly with underlying malignancy or chronic infection)
• Joint pains or rash (if autoimmune disease such as systemic lupus erythematosus is the trigger)

Causes and Risk Factors

Fibrinous pericarditis is usually a reaction to another disease process rather than a primary condition.

Common causes

• Infections: Viral (coxsackie, echovirus, adenovirus, influenza), bacterial (especially Staphylococcus aureus, Streptococcus), and mycobacterial (tuberculosis). Viral infections account for 60‑80 % of acute cases (CDC, 2022).
• Post‑myocardial infarction (Dressler syndrome): Autoimmune pericardial inflammation occurring weeks after an MI.
• Uremia: Advanced kidney failure (often with dialysis) can precipitate fibrinous pericarditis.
• Autoimmune diseases: Systemic lupus erythematosus, rheumatoid arthritis, scleroderma.
• Chest trauma or cardiac surgery: Direct injury or postoperative inflammation.
• Neoplasms: Primary cardiac tumors or metastases (lung, breast, melanoma).

Risk factors

• Recent viral illness
• History of myocardial infarction (especially < 6 weeks ago)
• Chronic kidney disease / dialysis
• Immunosuppression (HIV, organ transplantation)
• Autoimmune disease
• Recent thoracic radiation or major chest surgery

Diagnosis

Diagnosing fibrinous pericarditis relies on a combination of clinical assessment, imaging, and laboratory tests.

Step‑by‑step approach

1. History & physical exam: Identification of classic chest pain and detection of a pericardial friction rub.
2. Electrocardiogram (ECG): Diffuse ST‑segment elevation and PR‑segment depression in most leads; changes are usually uniform, unlike the localized patterns seen in MI.
3. Echocardiography (Echo): First‑line imaging; reveals pericardial thickening, possible small effusion, and confirms normal ventricular function.
4. Chest X‑ray: May show an enlarged cardiac silhouette if a large effusion is present; otherwise usually normal.
5. Laboratory tests:
   • Complete blood count (CBC) – leukocytosis if infectious.
   • Inflammatory markers – ESR, CRP (often markedly elevated).
   • Cardiac enzymes – usually normal; slight rise may suggest myopericarditis.
   • Renal function tests – assess for uremia.
   • Specific serologies – viral PCR, TB interferon‑gamma release assay, ANA, RF when indicated.
6. Advanced imaging (if needed): Cardiac MRI can differentiate pericardial inflammation from constrictive disease; CT is useful for assessing calcification or masses.
7. Pericardial fluid analysis: Rarely required; performed via pericardiocentesis when large effusion or tamponade is suspected. Fluid is examined for cell count, protein, glucose, culture, and cytology.

Treatment Options

The goals are to relieve pain, control inflammation, treat the underlying cause, and prevent complications.

Medications

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): First‑line for pain and inflammation. Common regimens:
  • Ibuprofen 600‑800 mg PO every 6‑8 h
  • Aspirin 750‑1000 mg PO every 6 h (especially post‑MI)
  Typical course: 1–2 weeks, then taper based on symptom resolution and inflammatory marker trends.
• Colchicine: Reduces recurrence risk. Dose 0.5 mg PO BID for adults (adjust for weight and renal function). Evidence shows a 30‑40 % reduction in recurrent pericarditis (ICMJE, 2021).
• Corticosteroids: Reserved for refractory cases or when NSAIDs/colchicine are contraindicated (e.g., severe uremia, autoimmune flare). Prednisone 0.2‑0.5 mg/kg/day, tapered over 4‑6 weeks. Long‑term use is avoided due to higher recurrence rates.
• Antibiotics/antitubercular therapy: Tailored to culture or PCR results when a bacterial or mycobacterial cause is identified.
• Uremia‑specific therapy: Intensified dialysis or initiation of renal replacement therapy.

Procedural interventions

• Pericardiocentesis: Indicated for large, symptomatic effusions or cardiac tamponade. Performed under echo‑guidance; fluid is analyzed.
• Pericardial window or subxiphoid pericardiostomy: Surgical drainage for recurrent or loculated effusions.
• Treatment of underlying disease: Revascularization after MI, immunosuppressive agents for autoimmune disorders, anti‑TB regimen for tuberculous pericarditis.

Lifestyle & supportive measures

• Rest and activity modification during acute phase (avoid heavy exertion).
• Maintain adequate hydration; avoid alcohol and tobacco, which can aggravate inflammation.
• Gradual return to normal activities once pain-free for 48 h and inflammatory markers have trended down.

Living with Fibrinous Pericarditis

Most patients recover fully with appropriate treatment, but a few may experience recurrent episodes. Practical tips help maintain quality of life.

• Medication adherence: Take NSAIDs and colchicine exactly as prescribed; never stop abruptly without consulting your doctor.
• Monitoring: Keep a symptom diary (pain intensity, triggers, medication timing). Record temperature if fever recurs.
• Follow‑up visits: Typically at 1‑2 weeks, then at 1‑month, and as needed. ECG and echocardiogram are repeated to confirm resolution.
• Exercise: Begin with gentle walking after you’re pain‑free; progress to moderate aerobic activity over 4‑6 weeks under physician guidance.
• Vaccinations: Annual influenza vaccine and COVID‑19 booster reduce viral triggers.
• Stress management: Chronic stress can modulate immune response; consider relaxation techniques (deep breathing, yoga).

Prevention

While not all cases are preventable, risk reduction strategies are valuable.

• Infection control: Hand hygiene, avoiding close contact with individuals with respiratory infections, and timely treatment of upper‑respiratory illnesses.
• Vaccination: Flu, COVID‑19, and pneumococcal vaccines have been shown to lower the incidence of viral‑induced pericarditis (WHO, 2022).
• Manage chronic conditions: Good control of diabetes, hypertension, and especially chronic kidney disease can lower the risk.
• Post‑MI care: Adhere to cardiac rehabilitation and anti‑platelet regimens to reduce the chance of Dressier syndrome.
• Avoid tobacco and excessive alcohol: Both increase systemic inflammation.
• Prompt treatment of autoimmune flares: Regular rheumatology follow‑up and adherence to disease‑modifying agents.

Complications

If left untreated or inadequately managed, fibrinous pericarditis may progress to serious conditions.

• Cardiac tamponade: Accumulation of fluid that compresses the heart, leading to hypotension and shock.
• Constrictive pericarditis: Chronic inflammation and scarring cause the pericardium to become rigid, impairing ventricular filling; occurs in 5‑15 % of untreated cases (Cleveland Clinic, 2023).
• Recurrent pericarditis: Up to 30 % experience recurrence within 3 months; risk rises with incomplete anti‑inflammatory therapy.
• Myocardial involvement (myopericarditis): Can lead to reduced ejection fraction, arrhythmias, or heart failure.
• Infectious spread: In bacterial or tuberculous pericarditis, untreated infection may disseminate.

When to Seek Emergency Care

Sources: Mayo Clinic. “Pericarditis.” 2023; CDC. “Viral Causes of Pericarditis.” 2022; NIH National Heart, Lung, & Blood Institute. “Pericardial Disease.” 2022; WHO. “Cardiovascular Disease Prevention.” 2022; Cleveland Clinic. “Constrictive Pericarditis.” 2023; International Colchicine Study Group. “Colchicine for Acute Pericarditis.” JACC, 2021.